Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.

Weakness in chip stocks was a reason for the latter group's issues, with the semiconductor fabless group the worst performer among the 197 IBD industry groups. Volume was up on the Nasdaq but lower on ...